This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Fosgemcitabine palabenamide
- DrugBank Accession Number
- DB15057
- Background
NUC-1031 is under investigation in clinical trial NCT03610100 (Acelarin First Line Randomised Pancreatic Study).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Fosgemcitabine palabenamide (DB15057)
- Weight
- Average: 580.482
Monoisotopic: 580.153457169 - Chemical Formula
- C25H27F2N4O8P
- Synonyms
- Acelarin
- BENZYL (2S)-2-((((2R,3R,5R)-5-(4-AMINO-2-OXO-PYRIMIDIN-1-YL)-4,4-DIFLUORO-3-HYDROXY-TETRAHYDROFURAN-2-YL)METHOXY-PHENOXY-PHOSPHORYL)AMINO)PROPANOATE
- Fosgemcitabine palabenamide
- Fosgemcitabine palabenamide, p(rs)-
- L-ALANINE, N-(2'-DEOXY-2',2'-DIFLUORO-P-PHENYL-5'-CYTIDYLYL)-, PHENYLMETHYL ESTER
- L-Alanine, N-[[P(S)]-2'-deoxy-2',2'-difluoro-P-phenyl-5'-cytidylyl]-, phenylmethyl ester
- N-[[P(S)]-2'-deoxy-2',2'-difluoro-P-phenyl-5'-cytidylyl]-L-alanine phenylmethyl ester
- External IDs
- BIO-1031
- NUC 1031
- NUC-1031
- NUC-1031, (S)-
- NUC1031
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmbroxol The risk or severity of methemoglobinemia can be increased when NUC-1031 is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when NUC-1031 is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when NUC-1031 is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when NUC-1031 is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when NUC-1031 is combined with Bupivacaine. - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- I17GWP65CE
- CAS number
- 1562406-27-2
- InChI Key
- NHTKGYOMICWFQZ-UHFFFAOYSA-N
- InChI
- InChI=1S/C25H27F2N4O8P/c1-16(22(33)36-14-17-8-4-2-5-9-17)30-40(35,39-18-10-6-3-7-11-18)37-15-19-21(32)25(26,27)23(38-19)31-13-12-20(28)29-24(31)34/h2-13,16,19,21,23,32H,14-15H2,1H3,(H,30,35)(H2,28,29,34)
- IUPAC Name
- SMILES
- CC(NP(=O)(OCC1OC(N2C=CC(N)=NC2=O)C(F)(F)C1O)OC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1
References
- General References
- Not Available
- External Links
- ChEMBL
- CHEMBL3126004
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Terminated Treatment Bile Duct Cancer 1 somestatus stop reason just information to hide 2 Terminated Treatment Ovarian Cancer 1 somestatus stop reason just information to hide 2, 3 Suspended Treatment Pancreatic Acinar Carcinoma / Pancreatic Neoplasms 1 somestatus stop reason just information to hide 1 Completed Treatment Ampullary Cancer / Bile Duct Cancer / Cholangiocarcinoma / Gallbladder Cancer 1 somestatus stop reason just information to hide 1 Completed Treatment Cancer 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at May 20, 2019 14:45 / Updated at June 21, 2024 20:32